New therapeutic agents in gastrointestinal stromal tumoursFalkenhorst, Johanna; Hamacher, Rainer; Bauer, SebastianCurrent Opinion in Oncology: July 2019 - Volume 31 - Issue 4 - p 322–328 doi: 10.1097/CCO.0000000000000549 SARCOMAS: Edited by Jean-Yves Blay Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review The aim of this study was to provide an update on the most recent developments regarding systemic treatments in the various molecular subtypes of gastrointestinal stromal tumour (GIST). Recent findings Several novel direct inhibitors of KIT and PDGFRA have entered the advanced clinical development in later treatment lines based on promising early clinical trial experience. Both avapritinib and ripretinib are more potent and more specific against various KIT and PDGFRA mutations. For patients with PDGFRA D842V mutations, the next generation of drugs may become the first active treatment options. Comprehensive molecular testing of KIT/PDGFRA-wildtype GIST may unmask clinically relevant targets, including NTRK fusions. Summary: The treatment landscape in GIST is expected to undergo a profound transformation with more potent drugs currently in late-stage clinical development. Sarcoma Center, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany Correspondence to Sebastian Bauer, Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, Essen 45122, Germany;. E-mail: firstname.lastname@example.org Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.